Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials
Search Refinements
Search Results: Clinical Trials
1-15 of 5212 results
Prothena scraps development of AL amyloidosis drug
By PBR Staff Writer
Prothena is stopping the development of AL amyloidosis treatment NEOD001 following unfavorable results in the phase 2b Pronto study.
Contract Research & Services > Clinical Trials > News
Managing your weight never tasted so good! New weight loss gummies,Visit us at booth E24 at Vitafoods 2018.
Nutrition is a trending topic for consumers today, but taste, convenience, and ease of use are also influencing purchasing decisions. With such demands from discerning consumers increase, and summer just around the corner, everybody is focused on getting their body in the best possible shape.
Contract Research & Services > Clinical Trials > Press Releases
Helperby Therapeutics’ combination antibiotic therapy is effective against WHO critical priority pathogen in phase 1 study
Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.
Contract Research & Services > Clinical Trials > News
Boehringer Ingelheim, Lilly, University of Oxford to study empagliflozin in chronic kidney disease
Boehringer Ingelheim and Eli Lilly and Company have entered into an academic collaboration with the University of Oxford to assess the effects of Jardiance (empagliflozin) on heart and kidney disease in adults with chronic kidney disease.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda significantly decreases risk of disease recurrence in melanoma study
Merck has reported results from the Phase 3 EORTC1325/KEYNOTE-054 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Tagrisso shows sustained PFS in phase 3 lung cancer trial
By PBR Staff Writer
AstraZeneca said that Tagrisso (osimertinib) in a first line setting has shown significant progression-free survival (PFS) benefit that was preserved through subsequent lines of therapy in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
Personalized tumor vaccine yields promising results in pilot trial
A new type of cancer vaccine has shown promise in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania.
Contract Research & Services > Clinical Trials > News
Futility forces Pfizer to stop phase 3 trial of Inlyta for recurrent renal cell carcinoma
By PBR Staff Writer
The independent data monitoring committee (DMC) has recommended the termination of a phase 3 clinical trial assessing Pfizer's Inlyta (axitinib) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy due to futility.
Contract Research & Services > Clinical Trials > News
UK Prime Minister unveils plans to tackle prostate cancer
By PBR Staff Writer
UK Prime Minister Theresa May has announced £75m of funding to support new research for early diagnosis and treatment of prostate cancer.
Contract Research & Services > Clinical Trials > News
AbbVie’s upadacitinib succeeds in phase 3 rheumatoid arthritis trial
By PBR Staff Writer
AbbVie’s rheumatoid arthritis drug upadacitinib (15mg, once-daily) has met its primary and secondary endpoints in the phase 3 Select-Compare clinical study.
Contract Research & Services > Clinical Trials > News
What's Hot at VFE2018 Softigel by Procaps
At this moment, what´s moving market growth are basically 3 aspects: - Aging population, were we see each day that senior consumers do not want to be defined by their age and wish to maintain their same active Lifestyle. - The FITNESS move, with consumers who are in search of preventive measures, instead of reactive measures in order to avoid future health problems. - And SELF-CARE: Since consumers are everyday more concerned with their wellbeing, new and more specialized Supplements need to be developed.
Contract Research & Services > Clinical Trials > Press Releases
Innovation that leads to transformation: Join us during CPhI and live the Softigel experience!
Softigel by Procaps will be attending CPhi North America´s second edition once again, our team of experts will be delighted to sit with you, discuss mutual opportunities and live the Softigel experience.
Contract Research & Services > Clinical Trials > Press Releases
Gel Technologies (Unigel, Gummygels, Chewgels, gtabs, versagel)
At Softigel we offer much more than traditional softgels, including everything from a single unit dosage form, to multiple delivery systems in a single dose.
Contract Research & Services > Clinical Trials > Products
Incyte and Merck's melanoma combo therapy fails in phase 3 trial
By PBR Staff Writer
A phase 3 study of Incyte’s epacadostat in combination with Merck’s Keytruda (pembrolizumab) in patients with unresectable or metastatic melanoma has failed meet to primary endpoint.
Contract Research & Services > Clinical Trials > News

PBR Supplier Recommendations

CTL Laboratories - Contract Immune Monitoring and Research
Cellular Technology Limited (CTL), headquartered in Shaker Heights, OH, is a privately held biotechnology company that built its reputation as the global leader in the ELISPOT field over the past two decades by establishing the ELISPOT instrumentation and scientific principles that have helped to define the parameters of ELISPOT research for monitoring of Cell-Mediated Immunity.... Contract Research & Services > Clinical Trials > Suppliers
See more

PBR White Paper Recommendations

Cellular Technology Limited: A multicolor Natural Killer cell-mediated cytotoxicity detection By CTL Laboratories
A multicolor Natural Killer cell-mediated cytotoxicity detection using fluorescence and direct cell imaging.... Contract Research & Services > Clinical Trials > White Papers User vs. Software-Dependent Variability of ELISPOT Counts Obtained from ten Different Laboratories By CTL Laboratories
In ELISPOT assays, cytokine spots produced by antigen-specific T cells show a broad spectrum of sizes and densities over variable background. Therefore, even experienced investigators are likely to come up with different spot counts when subjectively judging the minimal spot size/density to be counted and the maximal spot size for the cut off between singlecell-derived spots vs. those created by cell clusters. This study aims to find out whether statistics-based automated gating can harmonize spot counts obtained in different laboratories.... Contract Research & Services > Clinical Trials > White Papers ELISPOT Assays Provide Reproducible Results Among Different Laboratories for T-cell Immune Monitoring - Even in Hands of ELISPOT's Inexperienced Investigators By CTL Laboratories
Measurements of antibodies in bodily fluids (e.g., by ELISA) have provided robust and reproducible results for decades and such assays have been validated for monitoring of B-cell immunity. In contrast, measuring T-cell immunity has proven to be a challenge due to the need to test live cells in functional assays ex vivo. Several previous efforts looking into the reproducibility of ex vivo T-cell assays between different laboratories, or even within the same laboratory, have provided rather discouraging results.... Contract Research & Services > Clinical Trials > White Papers How Frequently are Predicted Peptides Actually Recognised by CD8 Cells? By CTL Laboratories
Detection of antigen-specific CD8 cells relies on the use of peptides that can bind to HLA-Class I molecules. There is extensive knowledge on individual HLA-alleles’ peptide binding requirements and for many antigens immunogenic peptides have been defined. The 32 individual peptides that comprise the CEF peptide pool represent such well-defined peptide determinants for Cytomegalo, Epstein Barr, and Flu virus. We tested 42 healthy human donors on the accuracy of these peptide predictions.... Contract Research & Services > Clinical Trials > White Papers Four-Colour B Cell ELISPOT Assay for Simultaneous Detection of all Four Human IgG Subclasses By CTL Laboratories
ELISPOT assays are a key research tool for enumerating antigen-specific B cells.... Contract Research & Services > Clinical Trials > White Papers See more
1-15 of 5212 results